HOLOGIC INC shareholders Q4 2022

HOLOGIC INC's ticker is HOLX and the CUSIP is 436440101. A total of 691 filers reported holding HOLOGIC INC in Q4 2022. The put-call ratio across all filers is 0.59 and the average weighting 0.2%.

HOLOGIC INC shareholders Q4 2022
NameSharesValueWeighting ↓
Blue Door Asset Management, LLC 90,533$6,772,7746.09%
Pavadi Capital LLC 82,117$6,143,1735.79%
Otter Creek Advisors, LLC 66,008$4,938,0593.23%
Bradley Mark J. 41,190$3,0812.74%
NIA IMPACT ADVISORS, LLC 61,137$4,573,6682.66%
SOUND SHORE MANAGEMENT INC /CT/ 902,863$67,543,1812.54%
Trinity Street Asset Management LLP 208,683$15,6112.53%
McGuire Investment Group, LLC 144,310$10,795,7942.34%
ATWOOD & PALMER INC 336,945$25,206,8502.28%
SANDLER CAPITAL MANAGEMENT 289,800$21,679,9382.22%
Lindenwold Advisors, INC 34,742$2,599,0491.74%
L2 Asset Management, LLC 36,173$2,706,0781.68%
LaFleur & Godfrey LLC 131,647$9,848,5121.64%
Eagle Ridge Investment Management 183,916$13,758,7561.60%
FIRST COMMUNITY TRUST NA 17,025$1,2741.48%
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE 10,000$748,1001.39%
Lingohr Asset Management GmbH 6,404$4791.34%
T. Rowe Price Investment Management, Inc. 23,376,904$1,748,8271.34%
Rodgers Brothers Inc. 88,510$6,621,4331.33%
Lombard Odier Asset Management (Switzerland) SA 220,714$16,511,6141.32%
About HOLOGIC INC

Hologic Inc: A Leader in Women's Health

Hologic Inc is a medical technology company that specializes in women's health. The company is headquartered in Marlborough, Massachusetts, and has operations in over 50 countries worldwide. Hologic's mission is to improve women's health through early detection and treatment of diseases such as breast cancer, cervical cancer, and osteoporosis.

Hologic's flagship product is the Genius 3D Mammography system, which is the first and only FDA-approved 3D mammography system. The system provides better detection of breast cancer than traditional 2D mammography, and reduces the need for additional imaging and biopsies. Hologic also offers a range of other products for breast cancer screening and diagnosis, including breast biopsy systems and breast MRI coils.

In addition to breast health, Hologic also offers products for cervical cancer screening, such as the ThinPrep Pap test and the Aptima HPV assay. The company also offers products for osteoporosis diagnosis and treatment, including the Horizon DXA system and the Fluoroscan InSight FD mini C-arm.

Hologic has a strong commitment to research and development, with over 1,200 patents and patent applications worldwide. The company invests heavily in clinical studies to ensure the safety and efficacy of its products, and has a team of over 1,000 scientists and engineers working to develop new technologies.

Overall, Hologic is a leader in women's health, with a strong focus on early detection and treatment of diseases. The company's innovative products and commitment to research make it a valuable partner for healthcare providers and patients alike.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists HOLOGIC INC's shareholders in Q4 2022. To view HOLOGIC INC's shareholder history, click here.